Study to Determine Efficacy and Safety of CC-486 With Nab-Paclitaxel Versus Nab-Paclitaxel in Patients With Chemotherapy naïve Metastatic Melanoma

Inclusion Criteria: * 1\. Histologically or cytologically confirmed cutaneous BRAF wild-type malignant melanoma with evidence of metastasis (Stage IV). 2\. No prior cytotoxic chemotherapy for metastatic malignant melanoma is permitted. No prior adjuvant cytotoxic chemotherapy is permitted. * Up to one prior regimen with the following classes of agents is permitted: o Targeted biologic agents (e.g. interleukin 2 \[IL-2\], granulocyte macrophage colony stimulating factor \[GM-CSF\], other cytokines or unarmed monoclonal antibodies) o Targeted small molecule inhibitors (e.g., kinase inhibitors, heat shock protein \[HSP\] inhibitors, etc.). * Immune checkpoint inhibitors (e.g. anti-CTLA4, anti-PD1, anti-PD-L1). * Prior adjuvant therapy with interferon and/or vaccines is permitted. * Prior treatments should be completed 4 weeks prior to enrollment in the study (ie, randomization). 3\. Male or non-pregnant and non-lactating female, and ≥ 18 years of age at the time of signing the informed consent document. * If heterosexually active, the subject must agree to use medical doctor-approved contraception throughout the study, and for 6 months after last dose of study drug. 4\. History of malignancy in the last 5 years; subjects with prior history of in situ cancer or basal or squamous cell skin cancer are eligible. * Subjects with other malignancies are eligible if they were cured by surgery (with or without radiotherapy) and have been continuously disease-free for at least 5 years. 5\. Radiographically-documented measurable disease (defined by the presence of at least one radiographically documented measurable lesion including measurable cutaneous metastasis). 6\. Adequate haemtological and biochemical parameters: * ANC ≥ 1.5 x 109 cells/L. * Platelets ≥ 100 x 109 cells/L. * Hgb ≥ 9 g/dL. * AST (SGOT) or ALT (SGPT) ≥ 2.5x upper limit of normal range (ULN); o ≤ 5.0 x ULN if hepatic metastases present. * Total bilirubin ≤ ULN. Creatinine ≤ 1.5 mg/dL. 8. ECOG performance status 0 to 1. Exclusion Criteria: * 1\. History of or current evidence of symptomatic brain metastases (brain Computed Tomography (CT)/Magnetic Resonance Imaging (MRI) is needed to exclude brain metastasis), including leptomeningeal involvement. 2\. Subject has pre-existing peripheral neuropathy of National Cancer Institute NCI Common Terminology Criteria for Adverse Events (NCI CTCAE) Scale of Grade ≥ 2. 3\. Prior radiation to a target lesion is permitted only if there has been clear progression of the lesion since radiation was completed.